Any meeting other than a type A or type B regarding the development and review of a product.

• A written response to questions posed in pre-IND or Type C meeting requests may be requested by the sponsor
• FDA may determine that a written response would be the most appropriate means for responding to a meeting request
• FDA shall notify the requester of the date it intends to send the written response
• FDA shall provide this notification within the specified time frame for responding to the meeting request